Bioworld Technology CO., Ltd.



CYP4F2 Peptide

Cat No.: BS5690P

Background

CYP4F isoforms are involved in the oxidation of important cellular mediators, such as leukotriene B4 (LTB4) and prostaglandins. CYP4F2 catalyzes omega-hydroxylation of LTB4 to a less potent proinflammatory eicosanoid, 20-OH-LTB4 as well as arachidonic acid. CYP4F2 is expressed in liver and kidney. Its expression is repressed by peroxisomal proliferators and induced by retinoic acid. X-linked adrenoleukodystrophy (X-ALD) is a severe neurodegenerative disorder biochemically characterized by elevated levels of very long-chain fatty acids (VLCFA). CYP4F2 participates in the omega-hydroxylation of VLCFAs, which may provide an alternative mode of treatment for X-ALD patients.

Swiss-Prot

P78329

Applications

Blocking

Specificity

This peptide can be used with studies using BS5690 CYP4F2 pAb.

Purification & Purity

Synthetic peptide CYP4F2. (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at $4 \, \mathbb{C}$ short term. Aliquot and store at $-20 \, \mathbb{C}$ long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.